Fol. Biol. 2020, 66, 117-122
PD-1, PD-L1 and PD-L2 Expression in Mantle Cell Lymphoma and Healthy Population
Cell surface expression of PD-1, PD-L1 and PD-L2 immune checkpoints on B and T cells obtained from patients with mantle cell lymphoma shows ambiguous results across many studies and creates obstacles for the implementation of immune checkpoint inhibitors into the therapy of mantle cell lymphoma. Using multiparameter flow cytometry we analysed surface expression of PD-1, PD-L1 and PD-L2 molecules on B and T cells of 31 newly diagnosed mantle cell lymphomas and compared it with the results of 26 newly diagnosed chronic lymphocytic leukaemias and 20 healthy volunteers. To gain insight into the age-dependent changes of surface expression of these immune checkpoints, flow cytometric subanalysis of 30 healthy volunteers of 25–93 years of age was conducted. Overall, we demonstrated weak surface expression of PD-1, PD-L1 and PD-L2 on B and T cells of mantle cell lymphoma patients (< 10 % when compared to healthy individuals). A significant age-dependent increase in the expression of PD-1 and its ligand PD-L2 was observed in healthy volunteers. Our results suggest that neither PD-1 nor its ligands represent relevant druggable targets for the therapy of mantle cell lymphoma. The observed age-dependent changes in healthy population could impact efficiency of immune checkpoint inhibitors and could be at least partly connected with increased incidence of cancer with age.
Keywords
mantle cell lymphoma, PD-1, PD-L1, PD-L2, B cells, T cells, immunosenescence.
Funding
The project was supported by Charles University Grant Agency Research Grant GA-UK 748318; Czech Ministry of Education, Youth and Sports Institutional Support PROGRES Q26/LF1 and PROGRES Q28/LF1; Charles University Centre of Excellence UNCE/MED/016; Specific University Research Programme SVV 260519.
References
Copyright
This is an open-access article distributed under the terms of the Creative Commons Attribution License.
